Transcode Therapeutics reports treatment of tumors using TTX-RIGA

TransCode Therapeutics reported successful treatment of preclinical melanoma tumors using its immunotherapy candidate, TTX-RIGA. The study showed a significant inhibition of tumor growth. In a mouse model of melanoma, systemic injection of TTX-RIGA demonstrated that the therapeutic candidate was effective in reducing primary tumor growth. It also elicited an immune response against secondary recurrent tumors, inhibiting their growth by 70%. This stands in contrast to intratumorally-administered standard RIG-I activators, which have demonstrated efficacy confined to the primary tumor. TransCode’s approach is designed to achieve persistent cell-mediated immunity by targeted activation of innate immunity in cancer cells within the tumor microenvironment. TransCode believes that its approach helps establish RIG-I as a clinically relevant target in oncology for a variety of solid tumors including melanoma, glioblastoma multiforme, pancreatic, colorectal and breast cancer, and especially tumors that are prone to recurrence after initial treatment.